Comme prévu, les actions américaines ont salué la victoire de Donald Trump tandis que les bourses européennes accusaient le coup, également lestées deux jours plus tard par une nouvelle déception sur le plan de relance chinois. Nos stratégies sectorielles et paniers de valeurs Trump (long ou short) ont fonctionné, avec quelques exceptions qui peuvent être des opportunités d’investissement, à l’instar de Total Energies ou Repsol. En Europe, nous conservons notre opinion Sous-pondérer s...
As expected, US equities welcomed Donald Trump's victory, while European stock markets reacted negatively, also weighed down two days later by a further disappointment on China's stimulus plan. Our sector strategies and baskets of Trump stocks (long or short) have paid off, with a few exceptions that may provide investment opportunities, like Total Energies or Repsol. In Europe, we are maintaining our Underweight recommendation on the Basic Resources, Chemicals, Luxury Goods and Autom...
>Outperform and target price of € 21.7 - Following the results publication and the conference call, we reiterate our Outperform recommendation on the stock (target price € 21.7). We have lowered our 2024-2026e EBITDA forecasts (-3% on average). Vallourec, despite a YTD performance close to 16%, is still showing a discount of 30% (in terms of 2025e EV/EBITDA) vs its main peer Tenaris. Vallourec is reducing its debt more quickly than expected (8 consecutive quarters of...
>Opinion Surperformance et OC 21.7 € réitérés - Post publication et conférence téléphonique, nous réitérons notre opinion Surperformance (OC 21.7 €). Nous avons ajusté nos attentes d’EBITDA 2024/26 à la baisse (-3% en moyenne). Vallourec, malgré une performance YTD proche de 16%, affiche toujours une décote de 30% (en VE/EBITDA 2025e) vs son principal comparable Tenaris. Vallourec se désendette plus rapidement qu’attendu (8 trimestres consécutifs de baisse de sa dette...
>Q3 2024 EBITDA 11% < expectations but faster-than-expected deleveraging - Q3 2024 EBITDA came to € 168m, down 22% vs Q2 2024 and below our estimate of € 189m (consensus € 192m). The EBITDA margin was 19%. Tubes EBITDA fell from € 193m in Q3 2023 to € 162m in Q3 2024 due to the fall in profitability in North America. Mine & Forest EBITDA was € 22m in Q3 2024, versus € 39m in Q3 2023, reflecting the decrease in iron ore production sold and lower selling price...
>EBITDA T3 24 11% < attentes mais un désendettement plus rapide qu’escompté - EBITDA T3 24 à 168 M€, en baisse de 22% par rapport au T2 2024, il est inférieur à nos prévisions de 189 M€ (consensus à 192 M€). La marge d’EBITDA est de 19%. EBITDA des Tubes passé de 193 M€ au T3 2023 à 162 M€ au T3 2024 en raison de la baisse de la rentabilité en Amérique du Nord. EBITDA Mine & Forêts à 22 M€ au T3 2024, contre 39 M€ au T3 2023, reflétant la diminution de la pr...
>Solid Q3 driven by resilient Europe and solid Brazil - ArcelorMittal released solid Q3 results with EBITDA of $ 1.58bn, down 15% QoQ and 26% y-o-y but 6% above consensus and 7% above ODDO BHF. The beat was mostly driven by resilient volumes and better costs (including raw mats) that offset lower shipments. By division, Brazil at $ 0.5bn was the sole higher vs Q2, thanks to better seasonality and good cost control. Despite a weaker environment, Europe at $0.4bn also ...
>Solid Q3 driven by resilient Europe and solid Brazil - ArcelorMittal released solid Q3 results with EBITDA of $ 1.58bn, down 15% QoQ and 26% y-o-y but 6% above consensus and 7% above ODDO BHF. The beat was mostly driven by resilient volumes and better costs (including raw mats) that offset lower shipments. By division, Brazil at $ 0.5bn was the sole higher vs Q2, thanks to better seasonality and good cost control. Despite a weaker environment, Europe at $0.4bn also ...
Aalberts: Building already bottoming, industry tough. Air France-KLM: Nobody helps. Alfen: Covenant agreement, hikes output Smart Grid. AMG: Sweet for 2024F, sour for 2025F. ArcelorMittal: 3Q24 EBITDA beats by 6%, FCF solid. BAM: 3Q beats, on its way to reach FY guidance. CMB.TECH: 3Q and FY24 reasonable but then more challenges. D'Ieteren: EGM and dividend dates announced; Belron US peer Boyd disappointing 3Q24. GBL: Double-digit TSR expected over 2024-27F. KBC: 3Q better acro...
ArcelorMittal S.A.: ArcelorMittal reports third quarter 2024 results Luxembourg, November 7, 2024 - ArcelorMittal (referred to as “ArcelorMittal” or the “Company” or the "Group") (MT (New York, Amsterdam, Paris, Luxembourg), MTS (Madrid)), the world’s leading integrated steel and mining company, today announced results1 for the three-month and nine-month periods ended September 30, 2024. 3Q 2024 key highlights: Safety focus: The Company-wide audit of safety by dss+ is now complete. It has provided the Group with a clear set of 6 recommendations which the Company is committed to implement....
ArcelorMittal announces the publication of its third quarter 2024 sell-side analyst consensus figures ArcelorMittal (‘the Company’) today announces the publication of its third quarter 2024 sell-side analyst consensus figures. The consensus figures are based on analysts’ estimates recorded on an external web-based tool provided and managed by an independent company, Visible Alpha. To arrive at the consensus figures below, Visible Alpha has aggregated the expectations of sell-side analysts who, to the best of our knowledge, cover ArcelorMittal on a continuous basis....
We are removing GSK from our European Large Caps Convictions List. The company is the only one of the six Big Pharma groups to have experienced a break in trend, which could act as a drag on future publications. Our analyst adjusted this morning his EPS estimates for 2024/2025/2026 by -0.6%, 2.0% and- 3.4% respectively, factoring in weaker growth for Arexvy and Shingrix, hence the lowering of his target price from 2,150p to 1,900p. - ...
Nous sortons GSK de notre liste de valeurs recommandées Large Caps. La société est la seule des 6 big Pharma à connaître une rupture de tendance qui pourrait peser lors des prochaines publications. Notre analyste ajuste ce jour ses prévisions de BPA 24/25/26 de -0.6%/-2.0%/-3.4% intégrant une plus faible croissance pour Arexvy et Shingrix, ce qui conduit à une baisse de son objectif de cours de 2 150p à 1 900p. - ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.